Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
An estimated one-third of the world population is latently infected with Mycobacterium tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs, such as isoniazid. We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria. In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity. Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymatic activity. This activity is blocked by nanomolar concentrations of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect. We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections. The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIGURE 4 ATP synthase is functional in dormant M. smegmatis . A , ATP synthesis activity in inverted membrane vesicles (50 𝛍 g/ml) from dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. Positive control was membrane vesicles with buffer containing ADP, P i , and NADH, whereas negative control excluded NADH and Pi from the assay buffer. B , effect of R207910 on membrane potential in dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. The membrane potential was measured using tetra-[ 3 H]phenylphosphonium bromide.](https://figures.cochat.ai/paper-figures/b01e7891765241e4a7d71c59f242a243/diarylquinolines-are-bactericidal-for-dormant-mycobacteria-as-a-result-of-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationM. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Cited by
Items 201–300 of 409
Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis
Greenstein, T., & Aldridge, B. B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1085946 · Cited by 18
“, 2020), target both replicating and non-replicating bacteria, and have been shown to be particularly potent against non-replicating bacteria induced by different microenvironmental conditions (Cho et al., 2007; Koul et al., 2008; Tasneen et al., 2011; Gold et al., 2015).”
BackgroundAn energetic profile of Corynebacterium glutamicum underpinned by measured biomass yield on ATP
Zelle, E., Pfelzer, N., Oldiges, M., Koch-Koerfges, A., Bott, M. H., Nöh, K., & Wiechert, W. (2021) · Metabolic Engineering · doi:10.1016/j.ymben.2021.03.006 · Cited by 18
Ahmad, Z., Mir, M. A., Sheikh, B. A., & Bhat, B. A. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666211222164938 · Cited by 18
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch14 · Cited by 18
Couturier, C., Silve, S., Morales, R., Pessègue, B., Llopart, S., Nair, A. C., Bauer, A., Scheiper, B., Pöverlein, C., Ganzhorn, A. J., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.035 · Cited by 18
Antitubercular In Vitro Drug Discovery: Tools for Begin the Search
Bueno, J. (2012) · InTech eBooks · doi:10.5772/29634 · Cited by 18
“These non-replicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs such as isoniazid (Koul et al., 2008).”
BackgroundProtein Turnover in Mycobacterial Proteomics
Rao, P., & Li, Q. (2009) · Molecules · doi:10.3390/molecules14093237 · Cited by 18
“Thus, there is an urgent medical need for new drugs and treatment regimens that can better manage the latent tuberculosis infection [7-9].”
BackgroundXie, M., Ganapathy, U. S., Lan, T., Osiecki, P., Sarathy, J. P., Dartois, V. A., Aldrich, C. C., & Dick, T. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00381-23 · Cited by 17
“aAssay extended to 10 days (instead of 5 days used for all other drugs) due to slow onset of bactericidal activity (16, 17).”
Tam, C. M., Yew, W.-W., & Yuen, K. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.19 · Cited by 17
Kumar, A., Kumari, N., Bhattacherjee, S., Venugopal, U., Parwez, S., Siddiqi, M. I., Krishnan, M. Y., & Panda, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114639 · Cited by 17
Design and Synthesis of Pyrano[3,2- b ]indolones Showing Antimycobacterial Activity
Monakhova, N., Korduláková, J., Vocat, A., Egorova, A., Lepioshkin, A., Salina, E. G., Nosek, J., Repková, E., Zemanová, J., Jurdáková, H., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00622 · Cited by 17
Laghari, M., Darwis, Y., Memon, A. H., Khan, A. A., Abdulbaqi, I. M., & Assi, R. A. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i1.28 · Cited by 17
“TMC-207 at 10 μg/mL was highly potent and killed dormant bacilli, as no bacteria could be detected by 14th day [45].”
Prevention and treatment of tuberculosis in solid organ transplant recipients
Abad, C. L. R., & Razonable, R. R. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1704255 · Cited by 17
“An attractive feature of bedaquiline is its equipotent activity against both replicating and dormant TB bacilli [96,97].”
BackgroundLobo, M. J., Ray, R., & Shenoy, G. G. (2020) · New Journal of Chemistry · doi:10.1039/d0nj02062a · Cited by 16
McNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 15
“, 2015) decreasing intracellular ATP levels (Koul et al., 2007; Koul et al., 2008; Koul et al., 2014).”
Perveen, S., Pal, S., & Sharma, R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00829d · Cited by 15
Jovanovic, A., Bright, F. K., Sadeghi, A., Wicki, B., Muñiz, S. E. C., Giannini, G. C., Toprak, S., Sauteur, L., Rodoni, A., Wüst, A., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-025-02217-y · Cited by 15
Gutti, G., Arya, K., & Singh, S. K. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190625165512 · Cited by 15
Bedaquiline: a new weapon against MDR and XDR-TB
Singh, H., Natt, N. K., Garewal, N., & Thangaraju, P. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130301 · Cited by 15
Potential of Mycobacterium tuberculosis Type II NADH-Dehydrogenase in Antitubercular Drug Discovery
Saha, P., Kumar, M., & Sharma, D. K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c01005 · Cited by 14
Proteomic characterization of Mycobacterium tuberculosis subjected to carbon starvation
Devlin, K. L., Leach, D. T., Stratton, K. G., Lamichhane, G., Lin, V., & Beatty, K. E. (2025) · mSystems · doi:10.1128/msystems.01530-24 · Cited by 14
“Bedaquiline is a diarylquinoline that targets ATP synthase, disrupting energy metabolism (43, 44, 97).”
Bustion, A. E., Ernest, J. P., Kaya, F., Silva, C., Sarathy, J. P., Blanc, L., Imperial, M. Z., Gengenbacher, M., Xie, M., Zimmerman, M. D., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf303 · Cited by 14
“…of patients with TB, we first measured the bactericidal activity of BDQ, the TBAJs, and their active metabolites against nonreplicating Mtb persisters in ex vivo caseum [3] after 14 days of incubation, given the documented slow onset of BDQ’s bactericidal activity [24, 39] (Supplementary Figure 6).”
Srinivas, V., Ruiz, R. A., Pan, M., Immanuel, S. R. C., Peterson, E. J. R., & Baliga, N. S. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100123 · Cited by 14
Mathiyazakan, V., Wong, C. F., Harikishore, A., Pethe, K., & Grüber, G. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01531-22 · Cited by 14
News on therapeutic management of MDR-tuberculosis: a literature review
Barthod, L., Lopez, J. G., Curti, C., Bornet, C., Roche, M., Montana, M., & Vanelle, P. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1338845 · Cited by 14
Kumar, A., Karkara, B. B., & Panda, G. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13934 · Cited by 14
Sviriaeva, E. N., Manimekalai, M. S. S., Grüber, G., & Pethe, K. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00449 · Cited by 14
Kumari, N., Sharma, R., Ali, J., Chandra, G., Singh, S., & Krishnan, M. Y. (2024) · Tuberculosis · doi:10.1016/j.tube.2024.102479 · Cited by 13
Liang, L., Lin, D., Chen, Y., Li, J., Liang, W., Zhao, H., Luo, W., Tian, G., & Feng, S. (2022) · mSystems · doi:10.1128/msystems.00209-22 · Cited by 14
“These chemotherapeutics suppress cellular ATP formation and therefore appear to be capable of killing dormant mycobacteria, unlike conventional chemotherapeutics (13, 14).”
BackgroundUmbrasas, D., Arandarčikaitė, O., Grigalevičiūtė, R., Stakauskas, R., & Borutaitė, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189717 · Cited by 12
“As a result, ATP synthesis is compromised and mycobacteria undergo cell death [36].”
BackgroundMehta, K., Guo, T., van der Graaf, P. H., & van Hasselt, J. G. C. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15925 · Cited by 12
Banerjee, U., Sankar, S., Singh, A., & Chandra, N. R. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.593497 · Cited by 12
“On the other hand, drugs like Bedaquiline, that target the ATP homeostasis are shown to have high efficacy in killing dormant bacteria as they target processes necessary for bacterial survival in dormancy (Koul et al., 2008; Rao et al., 2008; Kaushik et al., 2019).”
BackgroundEffects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs
Coleman, D., Waddell, S. J., & Mitchison, D. A. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq414 · Cited by 12
Troubles with Tuberculosis Prevention
Rubin, E. J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1312301 · Cited by 12
Vieira, V. H. D. C., Vieira, A. B. R., Pinheiro, W. B. D. S., Costa, S. D. P. S. E., Paiva, R. D. S., & Ribeiro, S. M. D. A. (2019) · Revista Pan-Amazônica de Saúde · doi:10.5123/s2176-6223201900037 · Cited by 11
Mulyukin, A. L., Recchia, D., Kostrikina, N. A., Artyukhina, M. V., Martini, B. A., Stamilla, A., Degiacomi, G., & Salina, E. G. (2023) · Microorganisms · doi:10.3390/microorganisms11112690 · Cited by 11
“In contrast, bedaquiline (TMC207), an ATP synthase inhibitor, effectively killed both replicating and dormant M. tuberculosis cells with the same target specificity [26].”
Understanding the key challenges in tuberculosis drug discovery: what does the future hold?
Zein-Eddine, R., Ramuz, M., Refrégier, G., Lutzeyer, J. F., Aleksandrov, A. V., & Myllykallio, H. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2531229 · Cited by 11
“It works by inhibiting mycobacterial ATP synthase, an essential enzyme for energy production in Mtb leading to cell death, making it effective against both replicating and dormant TB bacteria [18,19].”
ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines
Saxena, A. K., & Alam, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163515 · Cited by 11
The Perspectives of Combining Antibiotics with Saponins—Herbal Excipients
Makiej, A., Smułek, W., & Kaczorek, E. (2025) · Molecules · doi:10.3390/molecules30204102 · Cited by 11
“…can disrupt membrane architecture and functional integrity through the interaction of their lipophilic moieties with the bacterial membrane, sterically inhibit membrane-embedded proteins, or alter the proton motive force, potentially leading to cytosolic content leakage and cell death [42–44].”
Treatment options for children with multi-drug resistant tuberculosis
Bossù, G., Autore, G., Bernardi, L., Buonsenso, D., Migliori, G. B., & Esposito, S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2148653 · Cited by 10
“effect also on intracellular pathogens [31,32].”
Adolph, C., Hards, K., Williams, Z. C., Cheung, C., Keighley, L. M., Jowsey, W. J., Kyte, M., Inaoka, D. K., Kita, K., Mackenzie, J. S., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00655 · Cited by 10
Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
Minias, A. E., Żukowska, L., Lechowicz, E., Gąsior, F., Knast, A., Podlewska, S., Zygała-Pytlos, D., & Dziadek, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.618168 · Cited by 10
Sekiya, M. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00396 · Cited by 10
Navigating tuberculosis drug discovery with target-based screening
Miller, C. H., & O’Toole, R. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586999 · Cited by 10
“tuberculosis [31,32] but not Mycobacterium avium [33].”
BackgroundNew drugs for the management of tuberculosis
Cross, G. B. (2025) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001156 · Cited by 9
Sun, G., Wang, Q., Liang, Q., Song, X., Chen, J., Shi, J., Ma, W., Yuan, H., Jin, W., & Wang, Z. (2021) · Journal of International Medical Research · doi:10.1177/0300060520967611 · Cited by 9
Davis, N., Chionh, Y. H., McBee, M. E., Hia, F., Ma, D., Liang, C., Sharaf, M. L., Cai, W. M., Jumpathong, W., Levine, S. S., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06562-2 · Cited by 8
“4), the latter also observed in other mycobacteria 59 .”
InfluentialGomez, J. E., Clatworthy, A. E., & Hung, D. T. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.538663 · Cited by 8
Devasundaram, S., Khan, I., Kumar, N., Das, S. D., & Raja, A. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.04.017 · Cited by 8
“…down regulation of ATP ynthase operon (Karakousis et al., 2004), dormant mycobacteria o possess residual ATP synthase enzymatic activity, as observed in he present work, which is indispensable for its survival and making t a promising target to tackle dormant infections (Koul et al., 2008).”
BackgroundKorycka‐Machała, M., Kawka, M., Lach, J., Płocińska, R., Bekier, A., Dziadek, B. R., Brzostek, A. M., Płociński, P., Strapagiel, D., Szczesio, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1004632 · Cited by 8
“Bedaquiline is a diarylquinolone with activity against MDR-TB that is able to kill both actively replicating and dormant mycobacteria, thus shortening the duration of a treatment regime (Koul et al., 2008).”
BackgroundEvaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis
Martín-García, M., & Esteban, J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1867538 · Cited by 8
“replicating and non-replicating tubercle bacilli [18,19].”
Targeting Phenotypically Tolerant Mycobacterium tuberculosis
Gold, B. S., & Nathan, C. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch15 · Cited by 8
Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis
Ahmad, A., Akhtar, J., Ahmad, M. K., Khan, M. I., Wasim, R., Islam, A., & Singh, A. P. (2024) · Drug Research · doi:10.1055/a-2331-7061 · Cited by 7
“Because bedaquiline may function inside macrophages, it is the therapy of choice for multidrug-resistant tuberculosis; nevertheless, other Mycobacterium species exhibit substantial resistance to it [39, 40].”
BackgroundAbdelaal, H. F. M., Berube, B. J., Podell, B. K., Harband, M. H., Gary, H. E., Perez-Jaimes, M., Ackart, D. F., Reese, V. A., Larsen, S. E., Pecor, T., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00066-z · Cited by 7
“BDQ ’ s remarkable potency extends to both actively replicatingandnonreplicatingbacterialsubpopulations,asdemonstratedin variousstudies 26 – 28 .”
Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data
Goh, J. J., Patel, A. S., Ngara, B., van Wijk, R. C., Strydom, N., Wang, Q., Van, N., Washington, T. M., Nuermberger, E. L., Aldridge, B. B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111932 · Cited by 7
Nehru, V. J., Brammacharry, U., Ramkumar, S. R. S., Khusro, A., Vadakunnel, M. J., Gunasekaran, S., David, E., Priya, V. V., Aljowaie, R. M., & Almutairi, S. M. (2024) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2024.103226 · Cited by 7
Kandpal, M., Aggarwal, S., Jamwal, S. V., & Yadav, A. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_9 · Cited by 7
Shahbaaz, M., Cloete, R. E. A., Grobbelaar, M., Sampson, S. L., & Christoffels, A. G. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.05.108 · Cited by 7
A Importância do Núcleo Quinolínico e seus Derivados no Desenvolvimento de Fármacos.
Pinheiro, A. C., Bispo, M. L. F., & Souza, M. V. N. D. (2010) · Revista Fitos · doi:10.32712/2446-4775.2010.119 · Cited by 7
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Illarramendi, X., de Oliveira, M. L. W. D. R., Sales, A. M., Nery, J. A. D. C., & Sarno, E. N. (2013) · Clinical Investigation · doi:10.4155/cli.13.52 · Cited by 7
Pieterman, E. D., Sarink, M. J., Sala, C., Cole, S. T., de Steenwinkel, J. E. M., & Bax, H. I. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00280-20 · Cited by 7
“In summary, our results confirm the differences in activity of the different TB drugs against the active and nonmultiplying state that were expected based on the working mechanisms of these drugs (30, 31).”
ResultSi, A., Landgraf, A. D., Geden, S. E., Sucheck, S. J., & Rohde, K. H. (2022) · ACS Omega · doi:10.1021/acsomega.2c01887 · Cited by 7
Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis
Zhang, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211081109 · Cited by 7
“Drugs that have activity against nonreplicating tubercle bacilli (persisters) under hypoxic conditions, such as PZA (11), RIF (19), TMC207 (20), and PA-824 (21), are known to be important for shortening the duration of TB treatment (22).”
BackgroundAldrich, C. C., Boshoff, H. I., & Remmel, R. P. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc231 · Cited by 7
Čurillová, J., Pecháčová, M., Padrtová, T., Pecher, D., Mascaretti, Š., Jampílek, J., Pašková, Ľ., Bilka, F., Kováč, G., & Malík, I. (2021) · Applied Sciences · doi:10.3390/app12010300 · Cited by 6
“essential in the dormant state, because it carries specific features facilitating survival under nonreplicating conditions [16,17].”
BackgroundNitschke, J., Huber, R., Vossio, S., Moreau, D., Marcourt, L., Gindro, K., Queiroz, E. F., Soldati, T., & Hanna, N. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1439814 · Cited by 6
“In fact, in 2019, the first 6-month regimen for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB was approved, consisting of just three drugs with two novel mechanisms of action: bedaquiline, pretomanid, and linezolid (Koul et al., 2008; Conradie et al., 2020).”
BackgroundVerma, S. C., Venugopal, U., Khan, S. R., Akhtar, M. S., & Krishnan, M. Y. (2014) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2013.12.002 · Cited by 6
Drug Resistant Mycobacterium tuberculosis and New Drug Development
Patel, D. M., Patel, S. D., Jaiswal, P. S., & Brahmbhatt, K. J. (2012) · International Journal of Drug Development and Research · Cited by 6
Antituberculosis agents: Beyond medicinal chemistry rules
Pieroni, M. (2019) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2019.06.001 · Cited by 6
Martinecz, A., Boeree, M. J., Diacon, A. H., Dawson, R., Hemez, C. F., Aarnoutse, R. E., & Wiesch, P. A. Z. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011000 · Cited by 5
“In the latter case persisters are modelled as a subpopulation with high, 17x MIC (one of the higher estimates in the literature [43]).”
BackgroundAlghamdi, S. A., Qusty, N. F., Maulana, A., Ajmal, M., Khan, M., Mahato, A. K., Verma, S., & Asif, M. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023603257 · Cited by 5
Singh, S., Ng, P. S., Lakshmanan, U., Mathiyazakan, V., Wiggins, T. J., Lee, B. S., Ang, S. H., Sim, S. W. L., Santos, M. D., Moraski, G. C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01616 · Cited by 5
To eliminate tuberculosis, we must universally encourage treatment of its latent form
Schraufnagel, D. E. (2015) · Respirology · doi:10.1111/resp.12598 · Cited by 5
Metabolic Perspectives on Persistence
Hartman, T. E., Wang, Z., Jansen, R. S., Gardete, S., & Rhee, K. Y. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch31 · Cited by 5
Models and approaches for anti-TB drug testing
Yasinskaya, Y., & Sacks, L. V. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.64 · Cited by 5
Targeting Bacterial Persistence to Develop Therapeutics Against Infectious Disease
Hong‐Geller, E., & Micheva‐Viteva, S. (2015) · InTech eBooks · doi:10.5772/59404 · Cited by 5
Drug Resistant and Persistent Tuberculosis: Mechanisms and Drug Development
Zhang, Y. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_22 · Cited by 5
Saravanabavan, N., Shanmuganathan, P., & Kumarappan, M. (2020) · Annals of SBV · doi:10.5005/jp-journals-10085-8101 · Cited by 5
Essentiality of succinate metabolism in Mycobacterium tuberculosis
Adolph, C. (2021) · Otago University Research Archive (University of Otago) · Cited by 5
Kirubakar, G., Johnston, L., Lee, B. N. R., Russell, D. G., & Simwela, N. V. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00795-25 · Cited by 4
“BDQ and Pa are reported to be active against both replicating and non-replicating bacteria (40, 41).”
Kavanagh, M. E., McLean, K. J., Gilbert, S. H., Amadi, C. N., Snee, M., Tunnicliffe, R. B., Arora, K., Boshoff, H. I., Fanourakis, A., Rebollo-López, M. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00478 · Cited by 4
Patel, H., Ahmad, I., Jadhav, H., Pawara, R. H., Mundada, A. B., Shaikh, M., & Surana, S. J. (2020) · Reviews and Advances in Chemistry · doi:10.1134/s2079978020030048 · Cited by 4
First use of bedaquiline in a patient with XDR-TB in Singapore
Chua, A. P.-G., Hoo, G. S. R., Chee, C. B.-E., & Wang, Y. T. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-210961 · Cited by 4
Al-Ghafli, H., & Al‐Hajoj, S. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180731120544 · Cited by 4
Respiration and Oxidative Phosphorylation in Mycobacteria
Berney, M., & Cook, G. M. (2014) · Advances in photosynthesis and respiration · doi:10.1007/978-94-017-8742-0_15 · Cited by 4
Verma, N. (2016) · Apollo (University of Cambridge) · doi:10.17863/cam.13754 · Cited by 4
Advancements in photodynamic therapy for tuberculosis treatment
Lin, S., Zhang, Q., Liu, J., Lin, B., Zhao, D., Yang, J., Fang, J., Xu, J.-F., Pi, J., & Yang, F. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108207 · Cited by 3
Roy, A., Naik, D., Sau, S., Agnivesh, P. K., Parida, K. K., & Kalia, N. P. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c01066 · Cited by 3
Opportunities afforded by new drugs for tuberculosis
Churchyard, G., Friedland, G., Fielding, K., & Nardell, E. A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70095-5 · Cited by 3
ADVANCES IN ANTI-TUBERCULOSIS DRUGS
Pradhan, S., Mathur, A. G., & Patil, A. (2014) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v4i5.965 · Cited by 3
Kаyukova, L. A., Bismilda, V., Turgenbayev, K. A., Uzakova, A., Baitursynova, G., Jussipbekov, U. Z., Mukanova, M. S., Chingissova, L., Dyussembayeva, G., Borsynbayeva, A., et al. (2025) · Veterinary World · doi:10.14202/vetworld.2025.731-745 · Cited by 3
“Figure 1 illustrates the chemical structures of the drugs included in these regimens and their minimum bactericidal concentrations (MBCs) in the DS and MDR strains: bedaquiline [26, 27], pretomanid [28], linezolid [27, 29], moxifloxacin [27, 30], and clofazimine [27, 31].”
Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux
Guglielmetti, L., & Robert, J. (2015) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.12.003 · Cited by 3
Persistent Mycobacterium bovis -BCG is resistant to glutathione induced reductive stress killing
Patel, N., Lawrence, R., & Peteroy-Kelly, M. A. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.03.004 · Cited by 3
Vatlin, A. A., & Даниленко, В. Н. (2020) · Biology Bulletin Reviews · doi:10.1134/s2079086420060067 · Cited by 3
Molecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch21 · Cited by 3
Guillemont, J., Meyer, C., Koul, A., & Andries, K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-08-095167-6.00107-5 · Cited by 3
Self-citationNew drug candidates in tuberculosis treatment
Aksöz, B. E. (2014) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2014.35492 · Cited by 3
“Bedaquiline; çoğalan ve latent dönemde olan mikobakteriler üzerinde eşit düzeyde etki göstermektedir (50, 52, 54).”
Elliott, R. (2011) · Topics in medicinal chemistry · doi:10.1007/978-3-642-23487-3 · Cited by 3
Bedaquiline: A new hope in treatment of tuberculosis
Verma, A., Singh, A., Prakash, V., Kant, S., Kumar, R. K., Bhatia, A., & Srivastava, A. (2016) · International Journal of Health & Allied Sciences · doi:10.4103/2278-344x.187830 · Cited by 3
“Both replicating, as well as dormant Mycobacterium, are killed.([4]) Bedaquiline: A new hope in treatment of tuberculosis”
BackgroundSavvi, S. (2009) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 3
Metadata
- Authors
- Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (France) (FR)
- Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Koul, Anil
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 283
- Issue
- 37
- Pages
- 25273-25280
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2164282552
- Cited by
- 364
- References
- 31
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 10 · 2023: 19 · 2022: 16 · 2021: 22 · 2020: 23 · 2019: 25 · 2018: 17 · 2017: 25 · 2016: 15 · 2015: 20 · 2014: 29 · 2013: 20 · 2012: 22
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4495 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, Mycobacterium tuberculosis, dormant mycobacteria, latent tuberculosis infection, ATP synthase inhibition, ATP homeostasis, bactericidal activity, tuberculosis drug targets
- MeSH terms
- Adenosine Triphosphate, Antitubercular Agents, Homeostasis, Models, Biological, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Nitric Oxide, Oxygen, Quinolines, RNA, Messenger, Time Factors, Gene Expression Regulation, Bacterial, Mycobacterium smegmatis, Mitochondrial Proton-Translocating ATPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.